---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-122353"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:46:35.751500+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports positive exploratory endpoint from Phase 1b study of GT-02287 in Parkinson's Disease

## Summary
- GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.
- 19 of 21 enrolled participants completed 90-day dosing; 15 (79%) chose to continue in 9-month extension ending Sept 2026.
- Drug well-tolerated; data monitoring committee recommended study continue with no changes.
- Company has capital to fund operations through end of Phase 1b extension and year-end 2026.
- Phase 1 healthy volunteer study showed favorable safety, target engagement with increased GCase activity.

## SEC filing metadata
- accession: 0001104659-25-122353
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/0001104659-25-122353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/tm2533810d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-122353
- JSON: https://secwatch.observer/filing/0001104659-25-122353.json
- Plain text: https://secwatch.observer/filing/0001104659-25-122353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.